Tag Archives: Fovista®

Novartis signed licensing agreement with Ophthotech Corporation to market Fovista® outside the United States

Novartis acquires exclusive ex-US rights to Fovista from Ophthotech; upfront payment of USD 200 million plus potential future recruitment and other milestone payments; additionally Ophthotech to receive royalties on ex-US Fovista sales Fovista is the most advanced anti-PDGF technology in … Read the full press release